Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution
New York, New York, United States
Local Institution
Cincinnati, Ohio, United States
Start Date
November 1, 2004
Primary Completion Date
January 1, 2007
Completion Date
January 1, 2007
Last Updated
October 28, 2015
40
Estimated participants
cetuximab
DRUG
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions